Communiqués CStone Pharmaceuticals

Actions

2616

KYG2588M1006

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:09 02/10/2026			Varia. 5j.	Varia. 1 janv.
5,655 ^HKD	-4,15%		+6,00%	+7,31%

24/09	Le directeur général de CStone Pharma achète pour 2,7 millions de dollars de Hong Kong d’actions	MT
07/09	CStone Pharmaceuticals intègre le Stock Connect pour le trading Southbound	MT

Communiqués

31/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum	PR
31/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum	AQ
27/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum	PR
26/06	CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand	AQ
12/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights	EQ
11/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights	PR
01/06	ASCO 2026 \| CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept	PR
20/04	CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)	PR
26/03	CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0	PR
26/03	CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)	PR
23/02	CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC	AQ
16/02	CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 to Advance into Phase II Clinical Trial	AQ
16/02	CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial	PR
03/02	CStone Pharmaceuticals - Notice of Key Business Updates and Date of Board Meeting	AQ
07/11	ACAAI 2025 \| CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut	PR
13/10/25	ESMO 2025 Preview, CStone to Present Phase I Dose-Escalation Data for PD-1/VEGF/CTLA-4 Trispecific Antibody and Trial-in-Progress Update for ROR1 ADC	AQ
15/08/25	CStone Announces 2025 Interim Results, Pipeline Acceleration and Value Potential Unlocked	AQ
28/07/25	ESMO 2025, CStone to Debut CS2009 Clinical Data and CS5001 Trial Design	AQ
08/07/25	CStone Signs Exclusive License Agreement with Istituto Gentili for Sugemalimab in Western Europe and the UK	AQ
07/07/25	CStone Announces Clinical Progress Update on CS2009	AQ
04/07/25	Expanding into Autoimmunity and Inflammation, CStone Unveils Two Novel Bispecific Antibody Targets for Autoimmune, Inflammatory Diseases	AQ
24/03/25	CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer	AQ
05/03/25	CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody	AQ
26/02/25	CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab in JAMA	AQ
10/02/25	CStone Announces Inclusion of Cejemly as a First-Line Combination Therapy for NSCLC in ESMO Guideline	AQ